The EHA Research Roadmap: Normal Hematopoiesis.

International audienceIn 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1–2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cell-based Immune Therapies; and Gene Therapy

Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management

n/

The European Hematology Association Roadmap for European Hematology Research: a consensus document

The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at €23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine ‘sections’ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients

The European Hematology Association Roadmap for European Hematology Research. A Consensus Document

Abstract The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at Euro 23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine sections in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients. Received December 15, 2015. Accepted January 27, 2016. Copyright © 2016, Ferrata Storti Foundatio

Life cycle assessment of three Peruvian fishmeal plants: Toward a cleaner production

International audienc

Geological control of soil organic carbon and nitrogen stocks at the landscape scale

Parent material can deeply influence soil organic matter (SOM) stocks. In this study we tested the hypotheses that parent material had an effect on SOM concentrations and stocks and that this effect may be explained by the influence of soil parent material on basic soil parameters. However, as the factors known to influence SOM stocks such as land use and climate frequently co-vary with geology, testing the influence on SOM stocks of the factor “soil parent material” alone is challenging.To properly test our hypotheses, we studied SOM stocks of forest and cropland soils in a small landscape (17 km2) of the Paris basin (France), i.e. with an homogeneous climate. We collected topsoil samples (0–30 cm) in 50 forest and cropland plots, located in five geological contexts: loess deposit, mudstone, grainstone, chalk and calcareous clay deposits. Basic soil parameters (texture, pH, CaCO3 concentration) and SOM stocks to 30 cm depth (organic C and total N) were determined on the 50 soil samples.Organic C and total N concentrations and stocks in topsoils (0–30 cm) were much higher in forests than in cultivated soils (38.1 (± 12.8) vs. 19.0 (± 4.7) g C kg− 1 soil and 83.4 (± 19.8) vs 48.9 (± 9.9) t C ha− 1 for SOC concentrations and stocks respectively). The influence of land-use on organic C and total N concentrations and stocks was modulated by parent material (significant interactions between land-use and parent material, p < 0.05 for concentrations and stocks). Indeed, the difference in organic C and total N concentrations and stocks in topsoils (0–30 cm) was much lower for soils developed on loess deposits.While SOC concentration was significantly correlated to soil clay concentration for both cropland (r2 = 0.36, p < 0.001) and forest (r2 = 0.44, p < 0.001), there was no significant relation between SOC stocks and soil clay stocks for forest soil (p = 0.11) and a significant but highly scattered positive correlation between SOC and clay stocks in cropland soils (r2 = 0.20, p = 0.02). No significant relation between pH or CaCO3 and SOC stocks was observed. Our results therefore revealed that soil parent material can significantly influence topsoil (0–30 cm) organic C and N stocks but that more research is needed to understand how soil parent material influences SOM stocks as it cannot be simply explained by basic soil physico-chemical parameters (clay and carbonate concentrations or stocks, pH). Overall, our results suggest that a good knowledge of the geology is needed to better constrain SOC stocks as well as SOC stocks evolution in a changing environment from landscape to global scale

L’Asie du Sud-Est 2009 : les évènements majeurs de l’année

Chaque année l'Institut de recherche sur l'Asie du Sud-Est contemporaine (Irasec), basé à Bangkok, analyse les principaux événements politiques, économiques, sociaux, environnementaux ou religieux survenus dans l'ensemble du sous-continent asiatique. Plus de dix après la crise qui ébranla les économies asiatiques, l'Asie du Sud-Est est de nouveau confrontée à de graves difficultés qui mettent à mal ses modèles de développement économique et politique. S'agit-il seulement d'une crise de croissance d'une région prise dans la tourmente de l'économie mondiale ou bien est-ce que cette nouvelle dépression qui affecte l'ensemble des pays de la zone a des racines plus profondes ? Etablissant une rétrospective des événements majeurs de l'année 2008 ce livre aide à mieux comprendre les principaux enjeux de l'année 2009 dans une région en perpétuelle évolution et dont les soubresauts peuvent avoir des conséquences jusqu'en Europe. Grâce au travail tout au long de l'année d'une quinzaine de chercheurs et d'experts européens et asiatiques, Asie du Sud-Est 2009 tente de démêler l'éphémère des grandes tendances historiques et offre un décryptage pertinent et contemporain d'une actualité asiatique dense et multiforme. Outre une analyse passionante, cet ouvrage propose de nombreux outils pratiques tels qu'une chronologie détaillée de l'année, les adresses des différents centres de recherche francophones et européens travaillant sur l'Asie du Sud-Est, une bibliographie rassemblant les ouvrages publiés l'année dernière ou encore une liste des centres de documentation et des formations relatives à l'Asie du Sud-Est ainsi que les adresses de librairies spécialisées

A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the Lysa

International audienc